FIGS vs. Gildan Activewear: Which Consumer Stock Is a Better Buy in 2026?

FIGS posted FY 2025 revenue of nearly $631.1 million, up 13.6%, and net income of about $34.2 million versus $2.7 million a year earlier, but it trades at a premium 45.2x forward P/E and faces single-facility and supply-chain concentration risk. Gildan Activewear generated about $3.7 billion of revenue, $405.9 million of net income, and nearly $477.2 million of free cash flow, while trading at a lower 13.4x forward P/E and paying a dividend. The article’s conclusion favors Gildan for its steadier value profile, though the piece is largely comparative commentary rather than new company-specific catalyst news.

Analysis

The market is effectively pricing FIGS as a niche growth compounder while GIL is being treated like a slow-moving cash generator, but the asymmetry is more interesting than that. FIGS’ business quality is improving, yet its operating leverage is fragile because a single-node fulfillment footprint plus highly concentrated sourcing turns any localized disruption into an earnings event rather than a nuisance. That means the stock can rerate on good customer growth, but it can also de-rate sharply on issues that would barely register for a diversified apparel name.

GIL looks like the cleaner way to express a 2026 consumer/industrial apparel thesis because its valuation already discounts low growth, while its cash flow is robust enough to absorb commodity and labor volatility. The second-order winner here may be the less obvious adjacent suppliers and contract manufacturers that serve GIL’s scale model: if wholesale replenishment stays steady, the firm can pressure competitors on price without needing hero growth, which is exactly the kind of dynamic that squeezes subscale rivals. FIGS, by contrast, may still be forcing smaller medical-uniform peers to spend defensively on marketing, but the payoff period is long and customer concentration risk remains high.

The key contrarian point is that FIGS’ premium multiple is not justified by growth alone if operating cash conversion continues to lean on stock comp. If management can reduce SBC as a share of cash flow over the next 2-3 quarters while maintaining mid-teens revenue growth, the stock can work; if not, the market will likely re-rate it toward a lower-growth specialty retailer multiple. GIL’s main overhang is that the market may be underestimating how quickly cotton and input-cost deflation can drop through to earnings over the next 6-12 months, which would make the current valuation look cheap on forward earnings.

Net: this is less a beauty contest and more a quality-vs-fragility trade. For 2026, the better risk-adjusted setup is still GIL, while FIGS is a tactical momentum name only if investors are willing to underwrite execution risk and a supply-chain reset not in the base case.

Key Decisions for Investors

• Long GIL for 6-12 months as a valuation compression/FCF compounding trade; downside is more contained because the market already prices in modest growth, while any margin expansion from easing input costs can expand upside by 15-25% without needing multiple heroics.
• Avoid initiating a core long in FIGS at current levels; if long is desired, use a 3-6 month call spread instead of stock to cap downside from any fulfillment or sourcing shock while keeping upside exposure to continued customer growth.
• Pair trade: long GIL / short FIGS on a 6-9 month horizon; this isolates execution quality vs. niche-growth optimism and should work if the market re-prices FIGS’ concentration risk and SBC dependence.
• For FIGS holders, set a hard risk control around any supply-chain or distribution disruption headlines; the stock’s downside can gap quickly because the single-fulfillment-node risk is binary, not gradual.
• Add GIL on pullbacks rather than breakouts; the reward/risk improves if the stock sells off on temporary cotton volatility, since that is more likely to be transitory than structural.